- Home
- AGEN vs ENZ Comparison
AGEN vs ENZ Comparison
Compare AGEN & ENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- ENZ
- Stock Information
- Founded
- AGEN 1994
- ENZ 1976
- Country
- AGEN United States
- ENZ United States
- Employees
- AGEN N/A
- ENZ N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ENZ Medical Specialities
- Sector
- AGEN Health Care
- ENZ Health Care
- Exchange
- AGEN Nasdaq
- ENZ Nasdaq
- Market Cap
- AGEN 38.1M
- ENZ 34.2M
- IPO Year
- AGEN 2000
- ENZ N/A
- Fundamental
- Price
- AGEN $2.96
- ENZ $0.31
- Analyst Decision
- AGEN Buy
- ENZ
- Analyst Count
- AGEN 4
- ENZ 0
- Target Price
- AGEN $8.00
- ENZ N/A
- AVG Volume (30 Days)
- AGEN 655.0K
- ENZ 625.0K
- Earning Date
- AGEN 05-06-2025
- ENZ 06-12-2025
- Dividend Yield
- AGEN N/A
- ENZ N/A
- EPS Growth
- AGEN N/A
- ENZ N/A
- EPS
- AGEN N/A
- ENZ N/A
- Revenue
- AGEN $103,463,000.00
- ENZ $29,094,000.00
- Revenue This Year
- AGEN $4.03
- ENZ N/A
- Revenue Next Year
- AGEN $5.57
- ENZ N/A
- P/E Ratio
- AGEN N/A
- ENZ N/A
- Revenue Growth
- AGEN N/A
- ENZ N/A
- 52 Week Low
- AGEN $1.38
- ENZ $0.25
- 52 Week High
- AGEN $19.69
- ENZ $1.27
- Technical
- Relative Strength Index (RSI)
- AGEN 78.44
- ENZ 51.84
- Support Level
- AGEN $1.60
- ENZ $0.31
- Resistance Level
- AGEN $1.83
- ENZ $0.42
- Average True Range (ATR)
- AGEN 0.31
- ENZ 0.08
- MACD
- AGEN 0.21
- ENZ 0.01
- Stochastic Oscillator
- AGEN 97.52
- ENZ 47.99
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About ENZ Enzo Biochem Inc. ($0.01 Par Value)
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. The company has one reportable segment, Products, which focuses on labeling and detection technologies from DNA to whole cell analysis, including a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins.